1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Dilated Cardiomyopathy - Pipeline Review, H1 2016

Dilated Cardiomyopathy - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 59 pages

Dilated Cardiomyopathy - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Dilated Cardiomyopathy - Pipeline Review, H1 2016’, provides an overview of the Dilated Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
- The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects
- The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Dilated Cardiomyopathy - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dilated Cardiomyopathy Overview 6
Therapeutics Development 7
Pipeline Products for Dilated Cardiomyopathy - Overview 7
Dilated Cardiomyopathy - Therapeutics under Development by Companies 8
Dilated Cardiomyopathy - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Unknown Stage Products 11
Dilated Cardiomyopathy - Products under Development by Companies 12
Dilated Cardiomyopathy - Companies Involved in Therapeutics Development 13
Array BioPharma Inc. 13
Capricor Therapeutics, Inc. 14
Hemostemix Ltd 15
Kasiak Research Private Limited 16
Sanofi 17
Vericel Corporation 18
Dilated Cardiomyopathy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ACP-01 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
ARRY-797 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
CAP-1002 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
CIP-137401 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
DCM-1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Drugs for Dilated Cardiomyopathy - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
ixmyelocel-T - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Refacell-DCM - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Dilated Cardiomyopathy - Recent Pipeline Updates 41
Dilated Cardiomyopathy - Dormant Projects 51
Dilated Cardiomyopathy - Product Development Milestones 52
Featured News and Press Releases 52
Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T 52
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 52
Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack 52
Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T 53
Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting 53
May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients 54
May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions 55
Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T 55
Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 56
Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables
Number of Products under Development for Dilated Cardiomyopathy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Comparative Analysis by Unknown Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Dilated Cardiomyopathy - Pipeline by Array BioPharma Inc., H1 2016 13
Dilated Cardiomyopathy - Pipeline by Capricor Therapeutics, Inc., H1 2016 14
Dilated Cardiomyopathy - Pipeline by Hemostemix Ltd, H1 2016 15
Dilated Cardiomyopathy - Pipeline by Kasiak Research Private Limited, H1 2016 16
Dilated Cardiomyopathy - Pipeline by Sanofi, H1 2016 17
Dilated Cardiomyopathy - Pipeline by Vericel Corporation, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Dilated Cardiomyopathy Therapeutics - Recent Pipeline Updates, H1 2016 41
Dilated Cardiomyopathy - Dormant Projects, H1 2016 51

List of Figures
Number of Products under Development for Dilated Cardiomyopathy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 10
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) ...

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NADPH ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.